



NGS Process Overview


(Next Generation Sequencing for Biosafety Testing - A Primer)



September 2025
Colette Côté, Ph.D.
Chief Scientific and Portfolio Officer



Biologics Manufacturing At-A-Glance



Test Requirements:

Adventitious Agent Detection (Viral Safety) & Genetic Characterization

Traditional Biosafety Testing

Test Package Depends on Product & Regulatory Guidance

- Multiple, aging assays
- Includes animal-based testing
- Low resolution tests
- Extended timelines
- Increased cost




Classical Test Concerns:

- Resolution
- Specificity
- Lack of test system susceptibility
- Assay interference

Simplified Biosafety Testing

Goal: One Test Package To Replace Several Assays

- Animal and quasi-animal based testing (*in vivo*, HAP/MAP/RAP)
- PCR tests
- *In vitro* tests
- Immunoassays (9CFR)



Advantages

- Improved resolution
- Improved specificity
- Improved sensitivity
- Simplified matrix interference assessments/method adoption
- No need for neutralizing antibodies or other pre-work

A Historical Foray Into Sequencing

2000

Lynx Therapeutics launched the first NGS technology called [Massively parallel signature sequencing](#) (MPSS). The company was later bought by Illumina.

2014

Illumina launched the [HiSeq X Ten Sequencer](#) and the first \$1,000 genome. Illumina held 70% of the market for DNA sequencers accounting for over [90%](#) of all the DNA data produced globally.


First GMP NGS offered in the industry

2019

NHGRI reported the price of sequencing a complete human genome was \$942, beating Moore's Law prediction.

Today
NGS explicitly included in international regulatory guidance & incorporated into regulatory filings

A JOURNEY THROUGH THE HISTORY OF DNA SEQUENCING



A brief history of Next Generation Sequencing (NGS) ([frontlinegenomics.com](#))
A journey through the history of DNA sequencing ([the-dna-universe.com](#))

2008

The first NGS human genome sequencing [paper](#) was published. [James Watson's](#) personal genome sequence was handed to him on a hard drive and was estimated to cost \$1 million.

NGS enters the biosafety testing space


2018

Veritas Genetics offered whole genome sequencing that cost just \$199.

2022

Ultima Genomics launches the \$100 genome just 8 years after Illumina's HiSeq X Ten Sequencer breakthrough. Illumina counters it with the launch of NovaSeq X which promises to generate more than 20,000 whole genomes per year.

What's the Difference Between Sequencing Systems?



NGS is an advanced technology enabling analysis of millions to billions of individual DNA molecules rapidly & simultaneously


[Sanger is low throughput consensus sequencing]

NGS is sequence-agnostic—you don't need to know anything about the sequence to gain information about it

[Sanger is primer-dependent]

The Chemistry Explained

1st Gen (Sanger) Sequencing




SBS:

- Termination sequencing
- Determines consensus base for each position
- Individual forward and reverse reactions
- Primer-based
- Relatively low throughput

PATH: NGS Basics Sep 2025


2nd Gen (Illumina) Sequencing



SBS:

- Base addition sequencing
- Color-coded bases
- Chemistry limiting (short reads)
- Individual read sequencing of both strands
- Very high throughput
- Multiplexing capabilities

3rd Gen (ONT) Sequencing




Nanopore:

- Direct sequencing of RNA or DNA strand moving through nanopore
- Detects current through pores & each base has a specific signature
- Not chemistry limited (ultra-long)
- Individual read sequencing of RNA
- Medium throughput

NGS Simplified

Three Basic Steps



Considerations:


Critical Assay Elements:

- High quality sample processing = high quality data
- Smart bioinformatics (BFX)
- Fully validated, end-to-end GMP workflows
- Intermediate quality control steps (go/no-go gates)
- Appropriate assay controls

Bioinformatics

- Typically cloud-based computing, data storage & data transfer
- Scalable, dynamic environment
- Tailored BFX pipelines to meet current regulatory & client expectations
- Standardized databases/databanks for robust analysis
- Secondary qualification to minimize false positives

Diving Deeper into the Illumina Workflow



Starting Material

- Wide range of starting materials (cells, virus banks, reagents, etc.)
- May require pre-processing (e.g., (ultra)centrifugation, nuclease-treatment)

Nucleic Acid Extraction & QC Checks

- Extraction is process or sample type specific

Library Preparation & QC Checks

- Conversion of starting material to dsDNA for sequencing
- Adapter ligation/ addition of barcodes (indices) for clear sample identification & multiplexing


Sequencing & QC Checks

- Instrument preparation
- Sample pooling & dilution
- Sequencing
- Batching of samples is possible due to use of barcodes

Data Analysis

- Typically cloud-based analytics & storage
- Custom & routine analysis
- Agnostic or targeted analysis
- Demultiplex samples for individual data set analysis

Diving Deeper into the ONT Workflow



Starting Material

- Wide range of starting materials (cells, virus banks, reagents, etc.)
- May require pre-processing (e.g., (ultra)centrifugation, nuclease-treatment)

Nucleic Acid Extraction & QC Checks

- Extraction is process or sample type specific
- HMW DNA is desired for many ONT applications

Library Preparation & QC Checks

- Simplified sample preparation
- Direct sequencing of RNA or DNA
- Base calling done in real time

Sequencing & QC Checks

- Instrument preparation & flow cell check
- Sample pooling
- Sequencing
- Batching of samples is possible due to barcoding

Data Analysis

- Typically cloud-based analytics & storage
- Custom & routine analysis
- Agnostic or targeted analysis
- Demultiplex samples for individual data set analysis

Diving Deeper into Data Analysis




Starting Data Set

- Gigabytes to terabytes of data generated
- FASTQ or similar files
- Data integrity checks required
- Demultiplexing required if pooled samples

Quality Trimming/Pre-processing

- Removal of poor-quality reads
- Trimming of ends
- Adapter removal
- Optional removal of other specific sequences

Multistep Data Processing



Equipment & Infrastructure Considerations

Sample Processing

- **Standard molecular biology equipment:**
Required: vortex mixers, pipettors, centrifuges, thermocycler/heat blocks, fluorometer/spectrophotometer, electrophoresis equipment
Workflow specific: ultrasonicator (Covaris), ultracentrifuge, analytical balance
Nice to have (automation): nucleic acid extraction equipment (QIAGEN), liquid handler (PE, Tecan, Hamilton)
- **Equipment specific for quality control assessments (examples):**
 - **Fluorometer/spectrophotometer**
 - Qubit, Nanodrop, SpectraMax
 - **Electrophoresis equipment**
 - Bioanalyzer, Tapestation, Fragment Analyzer
- **Considerations:**
 - Throughput/scale
 - Equipment obsolescence
 - RUO vs 21 CFR Part 11/Annex 11 compliant
 - Integration with LIMS & other systems

Sequencing

- **Sequencer:**
 - **Long/all read:** ONT (MinION, GridION, PromethION), PacBio (Onso, Vega, Revio)
 - **Short read:** Illumina (MiSeq, NextSeq, NovaSeq), ABI Ion Torrent (Genestudio, Genexus)
 - Most QC is performed on-instrument
- **Considerations:**
 - Operating system
 - Throughput/scale
 - Required read lengths for analysis
 - Range of desired applications & supporting chemistries
 - Equipment obsolescence
 - RUO vs 21 CFR Part 11/Annex 11 compliant
 - Vendor lifecycle management
 - Software upgrades
 - Troubleshooting support

Data Analysis

- **Computing environment & supporting infrastructure:**
 - Cloud-based vs on-premise
- **Storage/archiving environment**
- **Data transfer/transit pathways & security checks**
- **Data analysis pipelines**
- **Supporting elements:**
 - Databases/databanks
- **Considerations:**
 - Operating system
 - Cloud provider & access to supporting validation documents
 - Open-source vs proprietary tools
 - Scalability & parallel processing
 - Lifecycle management
 - Data & infrastructure security
 - 21 CFR Part 11/Annex 11 compliance requirements
 - Data integrity checks
 - Electronic signatures
 - Access rights
 - Version control


Other Considerations

Workflow Controls

- **Nature of the controls – are they suitable to the application?**
 - In-parallel controls (positive and negative control samples)
 - Spiked-in controls (biological or synthetic, viral particles, nucleic acids)


Infected Cell Lines

- Better reflects typical test matrix in the industry
- Reflects natural virus infection patterns & replication lifecycle
- Variable MOI but can prepare ratios of infected to non-infected cells to assay sensitivity/LOD.



Intact Purified Viral Particles

- Broader spectrum of purified, characterized stocks available
- Quicker/simpler to use & most common spiking strategy
- Impact and kinetics of an active infection are lost
- Cannot be used to assess replication



Nucleic Acids


- Readily available stocks
- Easy to purify or synthesize & characterize
- Quick & simple to use
- Can be used to assess matrix effects
- Cannot be used to assess replication



- **Long term availability**
- **Level of characterization and available documentation**
- **Lot-to-lot consistency**

Quality Control Assessments

- **How many controls are needed?**
- **Where to place them?**
- **Nature of the assessment – quantitative/qualitative?**



Simplified Testing Strategy for Adventitious Agent Testing

Are Intact Cells Present?

Yes

Ex: MCB, WCB, EPOC,
Crude Bulk Harvest

Transcriptomic Assay

- 'Legacy' assay in the field
- RNA-based test designed to detect replicating viruses
- Controls in place to evaluate assay performance & matrix effects

- Simplified, 3Rs compliant testing strategy
- Rapid TATs with broad detection capabilities
- Detects all types of replicating viruses
- Exquisite sensitivity, comparable to PCR
- Published head-to-head comparability data with classical testing

No


Ex: Clarified Bulk Harvest,
DP, DS

Viromic Assay

- Typically targets intact viral particles in cell-free systems
- No neutralization antibodies required

Example: Transcriptomic Assay

Adventitious Agent Detection in Cell-based Materials




COMPARISON OF ADVENTITIOUS VIRUS DETECTION METHODS				
	In vivo	In vitro	PCR	NGS
Speed	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Compatibility	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Detection of unknowns	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Identification of unknowns	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Volume required	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Detection of live replicating virus	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆

- **Fast Turnaround Time**
 - *2-5 weeks; shorter than 28-day assay*
- **Low Input Sample Requirements**
 - *Preserves more sample for other uses*
- **May use long or short read sequencing capabilities**
- **May include specific controls to satisfy method adoption requirements**
- **May use RNA strandedness to assess active replication**
- **Head to head comparability results published**
- **LOD comparable or better than PCR assays**



Example: Viromic Assay

Adventitious Agent Detection in Cell-free Materials



COMPARISON OF ADVENTITIOUS VIRUS DETECTION METHODS


	In vivo	In vitro	PCR	NGS
Speed	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Compatibility	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Detection of unknowns	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Identification of unknowns	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Volume required	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆
Detection of live replicating virus	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆	☆☆☆☆☆

- **Fast Turnaround Time**
 - **3-6 weeks**
 - **Shorter TAT than 28 day assay**
- **Low Input Sample requirements**
 - **Preserves more sample for other uses**
- **May use long or short read sequencing capabilities**
- **Assesses all viral genome types present within viral particles**
- **LOD comparable or better than PCR assays**
- **Virus spiking studies used to assess matrix effects**




Other Applications in Vaccine Development

**Identity
Confirmation
of Engineered
Sequences**




Co-transfection

**Replication
Competency**




Residuals



AAV viral vectors will be packaged and assembled.


**Genome Integrity & Identity
(Variants/Truncations/Flip
flopping ITRs)**



Simplified Testing Strategy for Genetic Characterization

Identity Confirmation

- Microbe-specific characterization
- End-to-end characterization in a single NGS run
- Exquisite variant detection (typically down to ~5% of the population)
- Purity determinations/sub-population characterization



- Rapid TATs with comprehensive characterization capabilities
- Exquisite sensitivity


Integrity Assessment

- Evaluate intact versus truncated copies
- Evaluate encapsulated residuals
- Secondary identity confirmation

Thank you!



Biologics Quality Testing. Faster, Safer.



contact@pathoquest.com